Launching a New Leader in Precision Medicine
Hot genomics startup MedGenome engaged Merritt Group to bring broad awareness to the company’s unique oncology database and its integrated precision medicine capabilities.
Merritt Group developed a media strategy to highlight MedGenome’s technology platform and growth potential timed to its Series A and B funding announcements, in which the company was backed by impressive investors including Sequoia Capital and Mu Sigma.
Merritt Group worked closely with the client’s senior executives to develop messaging that positioned MedGenome as a worldwide leader in personalized cancer treatment strategies and poised for rapid growth. Then, the team executed a media strategy targeted at science, health and genomic reporters as well as reporters covering the hottest healthcare startups.
Results included more than 50 pieces of unique press coverage, including profile coverage in The Wall Street Journal, Reuters, TechCrunch, VentureBeat, Health Data Management, Dow Jones Health News, Genome Web, MedCity News, and many others, significantly raising the company’s profile in the global health market.